Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/jir.2020.0124 http://scihub22266oqcxt.onion/10.1089/jir.2020.0124 32960147!ä!32960147 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32960147&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Interferon+Cytokine+Res 2020 ; 40 (9): 438-442 Nephropedia Template TP {{tp|p=32960147|t=2020. Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience |pdf=|usr=}}{{32960147}} gab.com Text Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience JO: J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=32960147 #FOAvip A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-alpha2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-alpha2b (Heberon((R)) Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, P < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-alpha2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-alpha2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients. Twit Text FOAVip Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience ????J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=32960147 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32960147 #FOAvip English Wikipedia <ref>{{Cite pmid|32960147}}</ref> Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience #MMPMID32960147 Pereda R; Gonzalez D; Rivero HB; Rivero JC; Perez A; Lopez LDR; Mezquia N; Venegas R; Betancourt JR; Dominguez RE J Interferon Cytokine Res 2020[Sep]; 40 (9): 438-442 PMID32960147show ga A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-alpha2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-alpha2b (Heberon((R)) Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, P < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-alpha2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-alpha2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Child[MESH] |Child, Preschool[MESH] |Chloroquine/therapeutic use[MESH] |Coronavirus Infections/*drug therapy/mortality[MESH] |Cuba[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Infant[MESH] |Interferon alpha-2[MESH] |Interferon-alpha/*therapeutic use[MESH] |Lopinavir/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/mortality[MESH] |Prospective Studies[MESH] |Ritonavir/therapeutic use[MESH] |SARS-CoV-2[MESH]Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The (epmc).pdf DeepDyve Pubget Overpricing